Plant Name: Adiantum capillus-veneris
Taxonomic Information:
Plant ID: NPO9241
Plant Latin Name: Adiantum capillus-veneris
Taxonomy Genus: Adiantum
Taxonomy Family: Pteridaceae
Plant External Links:
NCBI TaxonomyDB:
13818
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
India; TurkmenistanTraditional Medicine System:
Indian Folk; UnaniMedicinal Functions:
Antidandruff; Antitussive; Depurative; Emmenagogue; Expectorant; Galactogogue; Refrigerant; Stings; Tonic; Vermifuge
Geographical Distribution:
India; Turkmenistan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| TDP1; PTGES; NOS2; ALOX15; USP2; BRCA1; | |
| PRKCE; MAPK1; EGFR; | |
| CA2; CA1; CA12; CA9; CA13; CA5B; CA7; CA4; CA6; | |
| ALOX5; MAOA; | |
| BACE1; | |
| MMP9; ANPEP; | |
| TLR9; | |
| HIF1A; | |
| EP300; | |
| SLC22A8; SLC22A6; | |
| HTT; NFE2L2; LMNA; F3; MAPT; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2C9; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | ANPEP | Aminopeptidase N | P15144 | CHEMBL1907 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Toll-like and Il-1 receptors | TLR9 | Toll-like receptor 9 | Q9NR96 | CHEMBL5804 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | Q16236 | CHEMBL1075094 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.651E-09 | 3.267E-06 | ANPEP, BRCA1, CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9, EP300, MMP9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.933E-09 | 3.508E-06 | CA2, CA4, CA9, EGFR, SLC22A6, SLC22A8, TLR9, TSHR |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 3.599E-07 | 3.135E-04 | ALOX5, APP, PTGES |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 5.392E-07 | 4.048E-04 | APP, EGFR, MAPT |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.826E-06 | 1.053E-03 | CA2, CA7, PRKCE |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 2.773E-06 | 1.244E-03 | BRCA1, HIF1A, HTT, LMNA, MMP9, NFE2L2 |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 5.158E-06 | 2.006E-03 | APP, EGFR, HIF1A, HTT, MAPK1, MAPT |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 6.958E-06 | 2.612E-03 | APP, BRCA1, CA2, CA9, EGFR, MAPK1, PRKCE, PTGES, SLC22A6 |
| CC | GO:0044464; cell part | GO:0030424; axon | 8.608E-06 | 3.073E-03 | APP, BACE1, CA2, HTT, MAPK1, MAPT |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 9.552E-06 | 3.152E-03 | APP, CA2, CA7, HIF1A, HTT, MAPK1, NPSR1, PRKCE |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.070E-05 | 3.368E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 1.128E-05 | 3.432E-03 | BRCA1, CA2, EP300, MAPK1 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.459E-05 | 3.922E-03 | BRCA1, EGFR, MAPK1, NFE2L2, NOS2, PRKCE |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.741E-05 | 4.351E-03 | ALOX15, BRCA1, HIF1A, HTT, MAPK1, MAPT, MMP9, PRKCE |
| BP | GO:0051179; localization | GO:0046903; secretion | 1.893E-05 | 4.530E-03 | ALOX5, ANPEP, APP, CA2, CA9, HIF1A, MAPK1, MMP9, NOS2, SLC22A6 |
| BP | GO:0009987; cellular process | GO:1901522; positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 2.051E-05 | 4.801E-03 | EP300, HIF1A, NFE2L2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 2.137E-05 | 4.847E-03 | APP, TLR9 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 2.478E-05 | 5.563E-03 | APP, CA4, EGFR, HTT, NOS2, PRKCE, PTGES, USP2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.803E-05 | 6.103E-03 | EGFR, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:0090322; regulation of superoxide metabolic process | 2.803E-05 | 6.103E-03 | EGFR, MAPT, NFE2L2 |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 3.305E-05 | 6.986E-03 | APP, BRCA1, EGFR, F3, HIF1A, LMNA, MAPK1, MMP9, NOS2, PTGES, TLR9, TSHR |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 3.618E-05 | 7.363E-03 | APP, EGFR, MAPK1, TLR9 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.544E-05 | 8.725E-03 | CA2, CA7, HTT, NPSR1, PRKCE |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 4.806E-05 | 9.101E-03 | ALOX15, ALOX5, PTGES |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 5.295E-05 | 9.671E-03 | EGFR, MAPK1, MMP9, NFE2L2 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 5.307E-05 | 9.671E-03 | ALOX15, BRCA1, HIF1A, MAPK1, NFE2L2, NOS2 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 5.329E-05 | 9.671E-03 | ALOX15, ALOX5 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 5.329E-05 | 9.671E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.000E-22 | 1.307E-17 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.098E-17 | 1.195E-13 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.183E-17 | 5.939E-13 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.942E-04 | 2.431E-02 | HTT, MAPT |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 2.273E-04 | 2.765E-02 | APP, BACE1, EGFR, MAPK1, SLC22A6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.420E-04 | 2.895E-02 | ALOX15, ALOX5, CYP2C9, NOS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.126E-21 | 3.167E-19 | CA12, CA1, CA5B, CA2, CA4, CA7, CA6, CA9, CA13 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.438E-08 | 4.051E-06 | CYP2C9, APP, MAOA, ALOX5, ALOX15, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.256E-06 | 6.239E-05 | NOS2, EP300, MAPK1, HIF1A, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.120E-06 | 1.907E-04 | CYP2C9, ALOX5, ALOX15, PTGES |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.609E-05 | 4.795E-04 | PRKCE, EP300, MAPK1, BRCA1, MMP9, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 8.134E-05 | 1.731E-03 | NOS2, EP300, MAPK1, HIF1A, MMP9, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 5.919E-05 | 1.470E-03 | MAPK1, MMP9, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.461E-04 | 3.834E-03 | EP300, MAPK1, HIF1A |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 2.556E-04 | 3.834E-03 | BACE1, APP, MAPK1, MAPT |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.573E-04 | 3.834E-03 | MAPK1, HIF1A, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.235E-04 | 6.000E-03 | MAPK1, HIF1A, MMP9, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 3.185E-04 | 4.286E-03 | NOS2, TLR9, EP300, MAPK1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.451E-04 | 4.286E-03 | EP300, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.932E-04 | 6.314E-03 | EP300, MAPK1, EGFR |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 8.574E-04 | 7.097E-03 | PRKCE, MAPK1, F3 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 8.090E-04 | 7.097E-03 | MAPK1, MMP9, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 8.574E-04 | 7.097E-03 | MAPK1, HIF1A, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 9.333E-04 | 7.319E-03 | NOS2, TLR9, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.344E-03 | 8.706E-03 | NOS2, ALOX5, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.344E-03 | 8.706E-03 | EP300, MAPK1, HIF1A |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 8.221E-04 | 7.097E-03 | CA2, CA4 |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 1.135E-03 | 8.458E-03 | MAPK1, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.310E-03 | 8.706E-03 | CYP2C9, ALOX15 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGES; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
